This Article Full Text Full Text (PDF) All Versions of this Article: 43/1/48    most recent 01.HYP.0000103629.01745.59v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dobrian, A. D. Articles by Prewitt, R. L. Search for Related Content PubMed PubMed Citation Articles by Dobrian, A. D. Articles by Prewitt, R. L.

(Hypertension. 2004;43:48.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity

From the Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Va.

Correspondence to Anca Dobrian, PhD, Assistant Professor, Department of Physiological Sciences, Eastern Virginia Medical School, 700W Olney Rd, Norfolk, VA 23507. E-mail dobriaad{at}evms.edu

The objective of this study was to determine the effect of pioglitazone on blood pressure (BP) and oxidative balance in obese, hypertensive, Sprague-Dawley rats and to identify some of the molecular mechanisms involved. After 12 weeks of a moderately high-fat diet, rats diverged into obesity-prone (OP) and obesity-resistant (OR) groups (n=6 per group). At the end of the diet, peroxisome proliferator activated receptor- (PPAR) mRNA expression and activity in the renal cortex and medulla of OP rats were significantly lower compared with that in OR rats. Pioglitazone treatment increased PPAR expression and activity in OP rats, suggesting a possible direct ligand-related effect of pioglitazone. As opposed to the untreated OP group, which showed moderate hypertension (systolic BP=159±5.3 mm Hg) after 12 weeks, pioglitazone-treated rats were normotensive (systolic BP=123.9±2.7 mm Hg). Insulin production was reduced by 2-fold in the OP group treated with pioglitazone. Urinary isoprostanes and renal lipid peroxides were also reduced in OP rats treated with pioglitazone compared with untreated counterparts. Also, expression of p47phox and gp91phox, both increased in OP versus OR rats, was reduced in the former by pioglitazone treatment. In addition, pioglitazone treatment increased nitrate/nitrite excretion and expression of renal endothelial and neuronal nitric oxide synthase. Collectively, the results show that pioglitazone treatment prevented hypertension and renal oxidative stress both by reducing free-radical production and by increasing nitric oxide production/availability.

Key Words: kidney • oxidative stress • free radicals • nitric oxide • vitamins

This article has been cited by other articles:

				I. Kuipers, P. van der Harst, G. Navis, L. van Genne, F. Morello, W. H. van Gilst, D. J. van Veldhuisen, and R. A. de Boer Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System Hypertension, June 1, 2008; 51(6): 1442 - 1448. [Full Text] [PDF]

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

				E. Grossman Does Increased Oxidative Stress Cause Hypertension? Diabetes Care, February 1, 2008; 31(Supplement_2): S185 - S189. [Abstract] [Full Text] [PDF]

				S. Tiwari, S. Riazi, and C. A. Ecelbarger Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes Am J Physiol Renal Physiol, October 1, 2007; 293(4): F974 - F984. [Abstract] [Full Text] [PDF]

				R. Liu, J. L. Garvin, Y. Ren, P. J. Pagano, and O. A. Carretero Depolarization of the macula densa induces superoxide production via NAD(P)H oxidase Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1867 - F1872. [Abstract] [Full Text] [PDF]

				H. Makino, Y. Miyamoto, K. Sawai, K. Mori, M. Mukoyama, K. Nakao, Y. Yoshimasa, and S.-i. Suga Altered Gene Expression Related to Glomerulogenesis and Podocyte Structure in Early Diabetic Nephropathy of db/db Mice and Its Restoration by Pioglitazone. Diabetes, October 1, 2006; 55(10): 2747 - 2756. [Abstract] [Full Text] [PDF]

				N. Ishizaka, Y. Ishizaka, H. Hashimoto, E.-I. Toda, R. Nagai, and M. Yamakado Metabolic Syndrome May Not Associate With Carotid Plaque in Subjects With Optimal, Normal, or High-Normal Blood Pressure Hypertension, September 1, 2006; 48(3): 411 - 417. [Abstract] [Full Text] [PDF]

				J. F. Carroll, W. J. Zenebe, and T. B. Strange Cardiovascular Function in a Rat Model of Diet-Induced Obesity Hypertension, July 1, 2006; 48(1): 65 - 72. [Abstract] [Full Text] [PDF]

				Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats FASEB J, June 1, 2006; 20(8): 1162 - 1175. [Abstract] [Full Text] [PDF]

				K. Ohashi, S. Kihara, N. Ouchi, M. Kumada, K. Fujita, A. Hiuge, T. Hibuse, M. Ryo, H. Nishizawa, N. Maeda, et al. Adiponectin Replenishment Ameliorates Obesity-Related Hypertension Hypertension, June 1, 2006; 47(6): 1108 - 1116. [Abstract] [Full Text] [PDF]

				R. Agarwal Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy Am J Physiol Renal Physiol, March 1, 2006; 290(3): F600 - F605. [Abstract] [Full Text] [PDF]

				M. Pesant, S. Sueur, P. Dutartre, M. Tallandier, P. A. Grimaldi, L. Rochette, and J.-L. Connat Peroxisome proliferator-activated receptor {delta} (PPAR{delta}) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovasc Res, February 1, 2006; 69(2): 440 - 449. [Abstract] [Full Text] [PDF]

				M. Herrera and J. L. Garvin Recent Advances in the Regulation of Nitric Oxide in the Kidney Hypertension, June 1, 2005; 45(6): 1062 - 1067. [Abstract] [Full Text] [PDF]

				J. B. Majithiya, A. N. Paramar, and R. Balaraman Pioglitazone, a PPAR{gamma} agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats Cardiovasc Res, April 1, 2005; 66(1): 150 - 161. [Abstract] [Full Text] [PDF]

				K. Rahmouni, M. L.G. Correia, W. G. Haynes, and A. L. Mark Obesity-Associated Hypertension: New Insights Into Mechanisms Hypertension, January 1, 2005; 45(1): 9 - 14. [Abstract] [Full Text] [PDF]

				Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF]

				F. J. Villarreal and J. Asbun Peroxisome Proliferator-Activated Receptors Ligands, Oxidative Stress, and Cardiac Fibroblast Extracellular Matrix Turnover Hypertension, November 1, 2004; 44(5): 621 - 622. [Full Text] [PDF]

				K. Chen, J. Chen, D. Li, X. Zhang, and J. L. Mehta Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-{gamma} Ligand Pioglitazone Hypertension, November 1, 2004; 44(5): 655 - 661. [Abstract] [Full Text] [PDF]

				R. M. Touyz Reactive Oxygen Species, Vascular Oxidative Stress, and Redox Signaling in Hypertension: What Is the Clinical Significance? Hypertension, September 1, 2004; 44(3): 248 - 252. [Abstract] [Full Text] [PDF]